Someone posted that a review of 60 small biotechs public companies that completed phase 2 trials for their drugs the median market cap was valued at $412M the mean market cap was $230M. It is interesting that Portages 35 percent interest. in Biohaven with several phase d2 or better drugs that have orphan status is valued for much less.
Market Data 
Markets 
AI
